Qiagen
Qiagen N.V., a leading global provider of sample and assay technologies, is headquartered in Germany (DE) and operates extensively across Europe, North America, and Asia. Founded in 1984, Qiagen has established itself as a key player in the biotechnology industry, focusing on molecular diagnostics, applied testing, and academic research. The company offers a diverse range of core products and services, including nucleic acid extraction kits, PCR reagents, and bioinformatics solutions, all designed to enhance the efficiency and accuracy of laboratory workflows. Qiagen's innovative technologies, such as its proprietary QIAamp® and QIAcube® systems, set it apart in the market. With a strong commitment to advancing precision medicine and diagnostics, Qiagen has achieved significant milestones, including partnerships with major healthcare institutions and a robust portfolio of patents. Its position as a trusted leader in the life sciences sector underscores its dedication to improving global health outcomes.
DitchCarbon Score
How does Qiagen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Qiagen's score of 99 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Qiagen's reported carbon emissions
In 2024, Qiagen reported total greenhouse gas emissions of approximately 334,410,000 kg CO2e, with Scope 1 emissions at about 11,378,000 kg CO2e, Scope 2 emissions (market-based) at approximately 3,461,000 kg CO2e, and a significant contribution from Scope 3 emissions, which totalled around 319,571,000 kg CO2e. This represents a slight decrease from 2023, where total emissions were about 351,424,000 kg CO2e. Qiagen has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 emissions by 42% by 2030 from a 2020 baseline. Additionally, the company has pledged to achieve a 90% reduction in absolute Scope 1, 2, and 3 emissions by 2050, also from a 2020 base year. For Scope 3 emissions specifically, Qiagen targets a 25% reduction by 2030, focusing on emissions from business travel, the use of sold products, and end-of-life treatment of sold products. Furthermore, Qiagen is committed to reaching net-zero greenhouse gas emissions across its entire value chain by 2050. This commitment includes ensuring that 67% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2027. These targets align with the Science Based Targets initiative (SBTi) and reflect Qiagen's dedication to addressing climate change and reducing its carbon footprint in the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 3,661,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 8,851,000 | - | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Qiagen is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
